133 related articles for article (PubMed ID: 31395608)
1. An Allosteric PRC2 Inhibitor Targeting EED Suppresses Tumor Progression by Modulating the Immune Response.
Dong H; Liu S; Zhang X; Chen S; Kang L; Chen Y; Ma S; Fu X; Liu Y; Zhang H; Zou B
Cancer Res; 2019 Nov; 79(21):5587-5596. PubMed ID: 31395608
[TBL] [Abstract][Full Text] [Related]
2. An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.
Qi W; Zhao K; Gu J; Huang Y; Wang Y; Zhang H; Zhang M; Zhang J; Yu Z; Li L; Teng L; Chuai S; Zhang C; Zhao M; Chan H; Chen Z; Fang D; Fei Q; Feng L; Feng L; Gao Y; Ge H; Ge X; Li G; Lingel A; Lin Y; Liu Y; Luo F; Shi M; Wang L; Wang Z; Yu Y; Zeng J; Zeng C; Zhang L; Zhang Q; Zhou S; Oyang C; Atadja P; Li E
Nat Chem Biol; 2017 Apr; 13(4):381-388. PubMed ID: 28135235
[TBL] [Abstract][Full Text] [Related]
3. The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex.
He Y; Selvaraju S; Curtin ML; Jakob CG; Zhu H; Comess KM; Shaw B; The J; Lima-Fernandes E; Szewczyk MM; Cheng D; Klinge KL; Li HQ; Pliushchev M; Algire MA; Maag D; Guo J; Dietrich J; Panchal SC; Petros AM; Sweis RF; Torrent M; Bigelow LJ; Senisterra G; Li F; Kennedy S; Wu Q; Osterling DJ; Lindley DJ; Gao W; Galasinski S; Barsyte-Lovejoy D; Vedadi M; Buchanan FG; Arrowsmith CH; Chiang GG; Sun C; Pappano WN
Nat Chem Biol; 2017 Apr; 13(4):389-395. PubMed ID: 28135237
[TBL] [Abstract][Full Text] [Related]
4. Allosteric Inactivation of Polycomb Repressive Complex 2 (PRC2) by Inhibiting Its Adapter Protein: Embryonic Ectodomain Development (EED).
Yang CY; Wang S
J Med Chem; 2017 Mar; 60(6):2212-2214. PubMed ID: 28256832
[TBL] [Abstract][Full Text] [Related]
5. Binding Modes of Small-Molecule Inhibitors to the EED Pocket of PRC2.
Huang D; Tian S; Qi Y; Zhang JZH
Chemphyschem; 2020 Feb; 21(3):263-271. PubMed ID: 31816138
[TBL] [Abstract][Full Text] [Related]
6. Discovery and Molecular Basis of a Diverse Set of Polycomb Repressive Complex 2 Inhibitors Recognition by EED.
Li L; Zhang H; Zhang M; Zhao M; Feng L; Luo X; Gao Z; Huang Y; Ardayfio O; Zhang JH; Lin Y; Fan H; Mi Y; Li G; Liu L; Feng L; Luo F; Teng L; Qi W; Ottl J; Lingel A; Bussiere DE; Yu Z; Atadja P; Lu C; Li E; Gu J; Zhao K
PLoS One; 2017; 12(1):e0169855. PubMed ID: 28072869
[TBL] [Abstract][Full Text] [Related]
7. Discovery of First-in-Class, Potent, and Orally Bioavailable Embryonic Ectoderm Development (EED) Inhibitor with Robust Anticancer Efficacy.
Huang Y; Zhang J; Yu Z; Zhang H; Wang Y; Lingel A; Qi W; Gu J; Zhao K; Shultz MD; Wang L; Fu X; Sun Y; Zhang Q; Jiang X; Zhang J; Zhang C; Li L; Zeng J; Feng L; Zhang C; Liu Y; Zhang M; Zhang L; Zhao M; Gao Z; Liu X; Fang D; Guo H; Mi Y; Gabriel T; Dillon MP; Atadja P; Oyang C
J Med Chem; 2017 Mar; 60(6):2215-2226. PubMed ID: 28092155
[TBL] [Abstract][Full Text] [Related]
8. EEDi-5285: An Exceptionally Potent, Efficacious, and Orally Active Small-Molecule Inhibitor of Embryonic Ectoderm Development.
Rej RK; Wang C; Lu J; Wang M; Petrunak E; Zawacki KP; McEachern D; Fernandez-Salas E; Yang CY; Wang L; Li R; Chinnaswamy K; Wen B; Sun D; Stuckey J; Zhou Y; Chen J; Tang G; Wang S
J Med Chem; 2020 Jul; 63(13):7252-7267. PubMed ID: 32580550
[TBL] [Abstract][Full Text] [Related]
9. Embryonic Ectoderm Development (EED) as a Novel Target for Cancer Treatment.
Cook N; Chen J; Zhou J; Wu D
Curr Top Med Chem; 2021; 21(31):2771-2777. PubMed ID: 34544341
[TBL] [Abstract][Full Text] [Related]
10. PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer.
Nagarsheth N; Peng D; Kryczek I; Wu K; Li W; Zhao E; Zhao L; Wei S; Frankel T; Vatan L; Szeliga W; Dou Y; Owens S; Marquez V; Tao K; Huang E; Wang G; Zou W
Cancer Res; 2016 Jan; 76(2):275-82. PubMed ID: 26567139
[TBL] [Abstract][Full Text] [Related]
11. SAR of amino pyrrolidines as potent and novel protein-protein interaction inhibitors of the PRC2 complex through EED binding.
Curtin ML; Pliushchev MA; Li HQ; Torrent M; Dietrich JD; Jakob CG; Zhu H; Zhao H; Wang Y; Ji Z; Clark RF; Sarris KA; Selvaraju S; Shaw B; Algire MA; He Y; Richardson PL; Sweis RF; Sun C; Chiang GG; Michaelides MR
Bioorg Med Chem Lett; 2017 Apr; 27(7):1576-1583. PubMed ID: 28254486
[TBL] [Abstract][Full Text] [Related]
12. Structure-Based Design of the Indole-Substituted Triazolopyrimidines as New EED-H3K27me3 Inhibitors for the Treatment of Lymphoma.
Dong G; Zuo J; Yu J; Xu J; Gao G; Li GB; Zhao W; Yu B
J Med Chem; 2023 Jan; 66(1):1063-1081. PubMed ID: 36580346
[TBL] [Abstract][Full Text] [Related]
13. A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine.
Catalano R; Rocca R; Juli G; Costa G; Maruca A; Artese A; Caracciolo D; Tagliaferri P; Alcaro S; Tassone P; Amodio N
Eur J Med Chem; 2019 Dec; 183():111715. PubMed ID: 31550663
[TBL] [Abstract][Full Text] [Related]
14. PICOT binding to the polycomb group protein, EED, alters H3K27 methylation at the MYT1 PRC2 target gene.
Pandya P; Pasvolsky R; Babichev Y; Braiman A; Witte S; Altman A; Isakov N
Biochem Biophys Res Commun; 2019 Feb; 509(2):469-475. PubMed ID: 30595380
[TBL] [Abstract][Full Text] [Related]
15. Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced Malignancies.
Huang Y; Sendzik M; Zhang J; Gao Z; Sun Y; Wang L; Gu J; Zhao K; Yu Z; Zhang L; Zhang Q; Blanz J; Chen Z; Dubost V; Fang D; Feng L; Fu X; Kiffe M; Li L; Luo F; Luo X; Mi Y; Mistry P; Pearson D; Piaia A; Scheufler C; Terranova R; Weiss A; Zeng J; Zhang H; Zhang J; Zhao M; Dillon MP; Jeay S; Qi W; Moggs J; Pissot-Soldermann C; Li E; Atadja P; Lingel A; Oyang C
J Med Chem; 2022 Apr; 65(7):5317-5333. PubMed ID: 35352560
[TBL] [Abstract][Full Text] [Related]
16. Identification and Assessments of Novel and Potent Small-Molecule Inhibitors of EED-EZH2 Interaction of Polycomb Repressive Complex 2 by Computational Methods and Biological Evaluations.
Zhu K; Du D; Yang R; Tao H; Zhang H
Chem Pharm Bull (Tokyo); 2020 Jan; 68(1):58-63. PubMed ID: 31685780
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Peptidomimetic Ligands of EED as Allosteric Inhibitors of PRC2.
Barnash KD; The J; Norris-Drouin JL; Cholensky SH; Worley BM; Li F; Stuckey JI; Brown PJ; Vedadi M; Arrowsmith CH; Frye SV; James LI
ACS Comb Sci; 2017 Mar; 19(3):161-172. PubMed ID: 28165227
[TBL] [Abstract][Full Text] [Related]
18. Astemizole arrests the proliferation of cancer cells by disrupting the EZH2-EED interaction of polycomb repressive complex 2.
Kong X; Chen L; Jiao L; Jiang X; Lian F; Lu J; Zhu K; Du D; Liu J; Ding H; Zhang N; Shen J; Zheng M; Chen K; Liu X; Jiang H; Luo C
J Med Chem; 2014 Nov; 57(22):9512-21. PubMed ID: 25369470
[TBL] [Abstract][Full Text] [Related]
19. Wedelolactone disrupts the interaction of EZH2-EED complex and inhibits PRC2-dependent cancer.
Chen H; Gao S; Li J; Liu D; Sheng C; Yao C; Jiang W; Wu J; Chen S; Huang W
Oncotarget; 2015 May; 6(15):13049-59. PubMed ID: 25944687
[TBL] [Abstract][Full Text] [Related]
20. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
Wang D; Jiang W; Zhu F; Mao X; Agrawal S
Int J Oncol; 2018 Sep; 53(3):1193-1203. PubMed ID: 29956749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
